“We were disheartened to see that the recent Eli Lilly Phase 3 clinical trials of a drug to treat Alzheimer’s disease has ended in failure,” stated GTX Corp. CEO, Patrick Bertagna. (Read the article on CNN here) “We all hope and pray for a cure to be found for all dementia. Unfortunately, we have to deal with the dangers of wandering until medical science can develop effective treatment, which is one of many reasons why GTX remains fully committed to providing innovative monitoring and recovery solutions to keep you connected to who and what matters most.”